JP2008063322A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008063322A5 JP2008063322A5 JP2007194146A JP2007194146A JP2008063322A5 JP 2008063322 A5 JP2008063322 A5 JP 2008063322A5 JP 2007194146 A JP2007194146 A JP 2007194146A JP 2007194146 A JP2007194146 A JP 2007194146A JP 2008063322 A5 JP2008063322 A5 JP 2008063322A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- disease caused
- hyperuricemia
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 201000001431 Hyperuricemia Diseases 0.000 claims 7
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 230000008694 endothelial dysfunction Effects 0.000 claims 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 2
- 229960000984 tocofersolan Drugs 0.000 claims 2
- 239000011732 tocopherol Substances 0.000 claims 2
- 229930003799 tocopherol Natural products 0.000 claims 2
- 235000019149 tocopherols Nutrition 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 210000003556 vascular endothelial cell Anatomy 0.000 claims 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 2
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 claims 2
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- 206010007027 Calculus urinary Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 claims 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 claims 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 claims 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 claims 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 1
- 206010034568 Peripheral coldness Diseases 0.000 claims 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- QEKBRBCVWVLFHH-QAKUKHITSA-L Tocopherol calcium succinate Chemical compound [Ca+2].[O-]C(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C.[O-]C(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C QEKBRBCVWVLFHH-QAKUKHITSA-L 0.000 claims 1
- 208000009911 Urinary Calculi Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- 235000017471 coenzyme Q10 Nutrition 0.000 claims 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims 1
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 claims 1
- 229960003765 fluvastatin Drugs 0.000 claims 1
- 208000034783 hypoesthesia Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 1
- 229960002797 pitavastatin Drugs 0.000 claims 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 1
- 229960002965 pravastatin Drugs 0.000 claims 1
- 229960001495 pravastatin sodium Drugs 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- 229940042585 tocopherol acetate Drugs 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 229960004747 ubidecarenone Drugs 0.000 claims 1
- 239000002076 α-tocopherol Substances 0.000 claims 1
- 235000004835 α-tocopherol Nutrition 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007194146A JP5226980B2 (ja) | 2006-08-10 | 2007-07-26 | ＨＭＧ−ＣｏＡリダクターゼ阻害剤、トコフェロール類及びＣｏＱ１０を含有する医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006217657 | 2006-08-10 | ||
| JP2006217657 | 2006-08-10 | ||
| JP2007194146A JP5226980B2 (ja) | 2006-08-10 | 2007-07-26 | ＨＭＧ−ＣｏＡリダクターゼ阻害剤、トコフェロール類及びＣｏＱ１０を含有する医薬組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012252097A Division JP2013032400A (ja) | 2006-08-10 | 2012-11-16 | ＨＭＧ−ＣｏＡリダクターゼ阻害剤、トコフェロール類及びＣｏＱ１０を含有する医薬組成物２ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008063322A JP2008063322A (ja) | 2008-03-21 |
| JP2008063322A5 true JP2008063322A5 (enExample) | 2010-07-29 |
| JP5226980B2 JP5226980B2 (ja) | 2013-07-03 |
Family
ID=39286323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007194146A Expired - Fee Related JP5226980B2 (ja) | 2006-08-10 | 2007-07-26 | ＨＭＧ−ＣｏＡリダクターゼ阻害剤、トコフェロール類及びＣｏＱ１０を含有する医薬組成物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5226980B2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012096998A (ja) * | 2009-02-27 | 2012-05-24 | Kowa Co | 安定なカプセル製剤及びその製造方法 |
| TWI636783B (zh) * | 2012-04-18 | 2018-10-01 | 友霖生技醫藥股份有限公司 | 含匹伐他汀（ｐｉｔａｖａｓｔａｔｉｎ）穩定配方的醫藥組合物 |
| WO2022129004A1 (en) * | 2020-12-15 | 2022-06-23 | Dsm Ip Assets B.V. | Coated statin tablet comprising vitamin e acetate powder |
| WO2022129003A1 (en) * | 2020-12-15 | 2022-06-23 | Dsm Ip Assets B.V. | Multiparticulate solid oral dosage form comprising statin and vitamin e |
| CN119915946B (zh) * | 2025-04-02 | 2025-06-17 | 凯莱谱科技股份有限公司 | 测定生物基质中辅酶q10浓度的方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4970692B2 (ja) * | 2000-05-09 | 2012-07-11 | 株式会社カネカ | 動脈硬化抑制方法及び組成物 |
| JP2002363073A (ja) * | 2001-05-09 | 2002-12-18 | Crescendo Corporation | スポーツパフォーマンス |
| JP2005187454A (ja) * | 2003-12-05 | 2005-07-14 | Sankyo Co Ltd | ビタミンｅ含有ｌｄｌ低下剤及び／又は動脈硬化抑制剤組成物 |
| JP2005225870A (ja) * | 2004-01-16 | 2005-08-25 | Sankyo Co Ltd | 血管内皮性酸化窒素の合成促進及び／又は内皮性酸化窒素血中濃度の維持・向上剤 |
-
2007
- 2007-07-26 JP JP2007194146A patent/JP5226980B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2022100434A (ru) | Фармацевтические композиции, содержащие epa и сердечно-сосудистое средство, и способы их применения | |
| HRP20241674T1 (hr) | 6'-[[(1s,3s)-3-[[5-(difluormetoksi)-2-pirimidinil]amino]ciklopentil]amino][1(2h),3'-bipiridin]-2-on kao inhibitor pcsk9 i postupci njegove upotrebe | |
| JP2010528011A5 (enExample) | ||
| JP2008063322A5 (enExample) | ||
| CL2011002787A1 (es) | Compuestos derivados de 1-cianoetilheterociclilcarboxamida sustituidos, inhibidores de dipeptidilpeptidasa i (dppi) o catepsina c; composicion farmaceutica; combinacion faramceutica; y su uso en el tratamiento del asma, la enfermedad obstructiva cronica o la rinitis alergica. | |
| CL2007002686A1 (es) | Compuestos derivados de 2h-isoquinolin-1-ona y 3h-quinazolin-4-ona, inhibidores de cinasa rho; y composicion farmaceutica, util para el tratamiento de una enfermedad o afeccion cardiovascular. | |
| JP2007277267A5 (enExample) | ||
| CL2007003495A1 (es) | Compuestos derivados de heterociclos condensados sustituidos, inhibidores de la actividad de la akt; composicion farmaceutica; y uso para el tratamiento o prevencion del cancer. | |
| RU2007126483A (ru) | Гетероциклические ингибиторы аспартилпротеазы | |
| WO2008045170A3 (en) | Statin and omega-3 fatty acids for reduction of apo-b levels | |
| ME02688B (me) | Hinazolinoni kao inhibitori humane fosfatidilinozitol 3 - kinaze delta | |
| CL2007001597A1 (es) | Compuestos derivados de 2-oxo-piridin-1(2h)-il-tiazol, imidazol o tiofen-carboxamida; composicion farmaceutica; y uso para el tratamiento de una enfermedad mediada por la estearoil-coa-desaturasa, tal como sindrome metabolico, hipertension y diabetes | |
| NZ595116A (en) | Use of rosuvastatin lactols as medicaments | |
| JP2016521279A5 (enExample) | ||
| CL2007003038A1 (es) | Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos. | |
| EA201401042A1 (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И КОМБИНИРОВАННОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ ИНГИБИТОРЫ HMG-CoA-РЕДУКТАЗЫ И ФОСФОДИЭСТЕРАЗЫ 4, И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ | |
| JP2006512361A5 (enExample) | ||
| DE112007001600A5 (de) | Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen | |
| WO2011011420A3 (en) | 3, 4-methylenedioxyphenyl inhibitors of gaba aminotransferase and/or gaba reuptake transporter inhibitor | |
| WO2009145591A3 (en) | Phenyl piperazine compounds, pharmaceutical composition including the same, and use thereof | |
| JP2005200419A5 (enExample) | ||
| JP2007534699A5 (enExample) | ||
| IL188449A0 (en) | Compositions to improve the bioavailability of polymethoxyflavones and tocotrienols for the treatment of cardiovascular disease | |
| JP2014521738A5 (enExample) | ||
| JP2008513379A5 (enExample) |